Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab), developed and marketed by Merck (known as MSD outside the U.S. and Canada), and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is approved based on data from Merck's Phase 3 KEYNOTE-189 trial, which enrolled patients regardless of PD-L1 expression and had dual primary endpoints of overall survival (OS) and progression-free survival (PFS).
Read more: https://prn.to/2MIngRa
Stay updated with the latest:
PharmeMed: https://www.pharmemed.com
LinkedIn: https://www.linkedin.com/company/pharmemed/
Twitter: https://twitter.com/PharmaJob
#fda #chemotherapy #cancer #pharmaceutical #healthcare #medical #lungcancer